down arrow

Metagenomi, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59102M1045
USD
1.66
0.02 (1.22%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.661.72

52 Week

1.234.40
Valuation
Technical
Day's Volume

CASH

317.4 k

Shareholding (Mar 2025)

FII

9.23%

Held by 19 FIIs

DII

73.1%

Held by 12 DIIs

Promoter

7.82%

How big is Metagenomi, Inc.?

22-Jun-2025

As of Jun 18, Metagenomi, Inc. has a market capitalization of 54.58 million and reported net sales of 45.26 million with a net profit of -77.95 million over the latest four quarters. Shareholder's funds are 234.86 million, and total assets amount to 324.60 million.

As of Jun 18, Metagenomi, Inc. has a market capitalization of 54.58 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 45.26 million, while the sum of net profit for the same period is -77.95 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 234.86 million, and total assets amount to 324.60 million.

Read More

What does Metagenomi, Inc. do?

22-Jun-2025

Metagenomi, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $25 million as of March 2025, with a market cap of $54.58 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -32.34%.

Overview:<BR>Metagenomi, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 54.58 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -32.34% <BR>Price to Book: 0.26<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Metagenomi, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Metagenomi, Inc. shows a mildly bearish trend despite recent outperformance against the S&P 500, with returns of 13.23% and 11.46% over the past week and month, but significant year-to-date and one-year losses of -40.72% and -19.55%.

As of 25 August 2025, the technical trend for Metagenomi, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show mild bullishness. The Bollinger Bands on the weekly chart are bullish, but the overall momentum remains weak with no signals from the RSI. <BR><BR>In terms of performance, Metagenomi has outperformed the S&P 500 over the past week and month, with returns of 13.23% and 11.46% respectively, compared to 1.05% and 2.33% for the index. However, year-to-date and one-year returns are significantly negative at -40.72% and -19.55%, underperforming the S&P 500's gains of 12.22% and 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Negative results in Jun 25

  • OPERATING CASH FLOW(Y) Lowest at USD -97.01 MM
  • NET SALES(Q) At USD 8.51 MM has Fallen at -57.45%
  • NET PROFIT(Q) At USD -18.62 MM has Fallen at -73.35%
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 70 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-39.14%

stock-summary
Price to Book

0.36

Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.43%
0%
-22.43%
6 Months
12.16%
0%
12.16%
1 Year
-46.62%
0%
-46.62%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Metagenomi, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Metagenomi Stock Forms Golden Cross, Signaling Bullish Breakout Ahead

Metagenomi Stock Forms Golden Cross, Signaling Bullish Breakout Ahead

Metagenomi, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The company has outperformed the S&P 500 over the past year and shows strong technical indicators, including a bullish MACD and On-Balance Volume trend, suggesting sustained investor interest and buying pressure.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
275.80%
EBIT Growth (5y)
-219.63%
EBIT to Interest (avg)
-88.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
3.59
Tax Ratio
6.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
46.47%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.30
EV to EBIT
1.78
EV to EBITDA
1.89
EV to Capital Employed
20.20
EV to Sales
-3.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1137.49%
ROE (Latest)
-32.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 15 Schemes (9.85%)

Foreign Institutions

Held by 19 Foreign Institutions (9.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -57.50% vs 76.99% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -85.98% vs 17.69% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.50",
          "val2": "20.00",
          "chgp": "-57.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.70",
          "val2": "-15.60",
          "chgp": "-26.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.90",
          "val2": "-10.70",
          "chgp": "-85.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,465.30%",
          "val2": "-842.80%",
          "chgp": "-162.25%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.74% vs 160.47% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.35% vs -56.65% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.30",
          "val2": "44.80",
          "chgp": "16.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-83.50",
          "val2": "-74.30",
          "chgp": "-12.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.20",
          "val2": "2.90",
          "chgp": "-417.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-78.10",
          "val2": "-68.30",
          "chgp": "-14.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,700.00%",
          "val2": "-1,753.80%",
          "chgp": "5.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
8.50
20.00
-57.50%
Operating Profit (PBDIT) excl Other Income
-19.70
-15.60
-26.28%
Interest
0.00
0.00
Exceptional Items
-1.30
0.00
Consolidate Net Profit
-19.90
-10.70
-85.98%
Operating Profit Margin (Excl OI)
-2,465.30%
-842.80%
-162.25%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -57.50% vs 76.99% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -85.98% vs 17.69% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
52.30
44.80
16.74%
Operating Profit (PBDIT) excl Other Income
-83.50
-74.30
-12.38%
Interest
0.00
0.00
Exceptional Items
-9.20
2.90
-417.24%
Consolidate Net Profit
-78.10
-68.30
-14.35%
Operating Profit Margin (Excl OI)
-1,700.00%
-1,753.80%
5.38%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.74% vs 160.47% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14.35% vs -56.65% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Metagenomi, Inc. stock-summary
stock-summary
Metagenomi, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."